Atlas' 2022 fund, which raised the same amount and supported the launch of 16 companies, ended up backing four companies or programmes that went on to be acquired by big pharma groups (Nimbus ...

Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast ...

This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a positive sign for private ...

To register for the webcast, click here. Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ...

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal ...

MIAMI, May 16, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective ...

MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 94,050 ...

The NIMBUS workstation comes in three highly configurable open or enclosed platforms: NIMBUS96 : 96-channel multi-pipetting head (MPH) NIMBUS384 : 384-channel multi-pipetting head (MPH) ...

Shawn K. Singh is a businessperson who has been at the head of 9 different companies and occupies the position of Chief Executive Officer & Director at VistaGen Therapeutics, Inc. and Chief ...

MIAMI, May 16, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective ...

Dr. Hedrick is the founder of Plus Therapeutics, Inc. with the title of President, Chief Executive Officer & Director (2019-present). Former positions include President, Chief Executive Officer ...

Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ...